Editas Medicine Inc (EDIT)

Nov 20, 2024

EDIT Stock Drops Amid Market Volatility in Biotech Sector - GuruFocus.com

Nov 20, 2024

Nov 20, 2024

Little Excitement Around Editas Medicine, Inc.'s (NASDAQ:EDIT) Revenues As Shares Take 34% Pounding - Simply Wall St

Nov 20, 2024

Nov 20, 2024

Editas Q3 Loss Narrower Than Expected, Revenues Decrease Y/Y - MSN

Nov 20, 2024

Nov 18, 2024

Editas Medicine, Inc. (NASDAQ:EDIT) Short Interest Update - MarketBeat

Nov 18, 2024

Nov 16, 2024

Editas Medicine stock hits 52-week low at $2.7 amid market challenges - Investing.com India

Nov 16, 2024

Nov 12, 2024

Editas Medicine's SWOT analysis: gene editing stock faces pivotal phase - Investing.com

Nov 12, 2024

Nov 08, 2024

Cantor Fitzgerald Expects Lower Earnings for Editas Medicine - MarketBeat

Nov 08, 2024

Nov 08, 2024

FY2024 EPS Estimate for Editas Medicine Raised by Analyst - MarketBeat

Nov 08, 2024

Nov 07, 2024

Vertex Pharmaceutic (VRTX-Q) QuotePress Release - The Globe and Mail

Nov 07, 2024

Nov 07, 2024

TSX Real Estate Capped Index (TTRE) QuotePress Release - The Globe and Mail

Nov 07, 2024

Nov 07, 2024

TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail

Nov 07, 2024

Nov 07, 2024

Dow Jones Industrials Average (DOWI) QuotePress Release - The Globe and Mail

Nov 07, 2024

Nov 07, 2024

TSX Global Gold Index (TTGD) QuotePress Release - The Globe and Mail

Nov 07, 2024

Nov 07, 2024

TSX Oil and Gas EW Index (TXOE) QuotePress Release - The Globe and Mail

Nov 07, 2024

Nov 07, 2024

S&P 500 Index (INX) QuotePress Release - The Globe and Mail

Nov 07, 2024

Nov 07, 2024

Bristol-Myers Squibb Company (BMY-N) QuotePress Release - The Globe and Mail

Nov 07, 2024

Nov 07, 2024

Gene Therapy Market to Grow by USD 6.74 Billion from 2024-2028, as Rise in Special Drug Designations Drives Demand with AI-Powered Market EvolutionTechnavio - The Malaysian Reserve

Nov 07, 2024

Nov 07, 2024

FY2024 EPS Estimate for Editas Medicine Lifted by Analyst - MarketBeat

Nov 07, 2024

Nov 07, 2024

Editas Medicine, Inc. (NASDAQ:EDIT) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat

Nov 07, 2024

Nov 06, 2024

Editas Medicine upgraded at Evercore on CRISPR platform - Seeking Alpha

Nov 06, 2024

Nov 06, 2024

Editas Medicine to Participate in Upcoming Investor Conferences - GlobeNewswire

Nov 06, 2024

Nov 06, 2024

Editas Medicine to Present at 3 Major Healthcare Investor Conferences | EDIT Stock | EDIT Stock News - StockTitan

Nov 06, 2024

Nov 06, 2024

Analysts Are Betting On Editas Medicine, Inc. (NASDAQ:EDIT) With A Big Upgrade This Week - Simply Wall St

Nov 06, 2024

Nov 06, 2024

Growth Investors: Industry Analysts Just Upgraded Their Editas Medicine, Inc. (NASDAQ:EDIT) Revenue Forecasts By 19% - Yahoo Finance

Nov 06, 2024

Nov 06, 2024

Editas downgraded to market perform by Raymond James - MSN

Nov 06, 2024

Nov 05, 2024

Editas Medicine (FRA:8EM) Total Inventories : €0.00 Mil (As of Sep. 2024) - GuruFocus.com

Nov 05, 2024

Nov 05, 2024

Chardan Capital Reiterates Buy Rating for Editas Medicine (NASDAQ:EDIT) - MarketBeat

Nov 05, 2024

Nov 05, 2024

Editas Medicine Buy rating and $12 target reaffirmed by Chardan - Investing.com UK

Nov 05, 2024

Nov 05, 2024

Chardan Capital Markets Reiterates Buy Rating on Editas Medicine (EDIT) - StreetInsider.com

Nov 05, 2024

Nov 05, 2024

Editas Medicine Downgraded by Raymond James Amid Strategic Shift and Program Uncertainty - GuruFocus.com

Nov 05, 2024

Nov 05, 2024

Editas Medicine maintains Perform rating at Oppenheimer By Investing.com - Investing.com UK

Nov 05, 2024

Nov 05, 2024

Royal Bank of Canada Lowers Editas Medicine (NASDAQ:EDIT) Price Target to $5.00 - MarketBeat

Nov 05, 2024

Nov 05, 2024

Editas Medicine (NASDAQ:EDIT) Issues Quarterly Earnings Results, Hits Expectations - MarketBeat

Nov 05, 2024

Nov 05, 2024

Editas Medicine target cut to $5 by Barclays on strategic outlook - Investing.com Canada

Nov 05, 2024

Nov 05, 2024

Editas Medicine Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance

Nov 05, 2024

Nov 05, 2024

Editas Medicine (EDIT) PT Lowered to $5 at Barclays - StreetInsider.com

Nov 05, 2024

Nov 05, 2024

Editas Medicine (EDIT) Reports Q3 Loss, Misses Revenue Estimates - MSN

Nov 05, 2024

Nov 05, 2024

Truist cuts Editas Medicine target to $8, keeps buy rating By Investing.com - Investing.com Canada

Nov 05, 2024

Nov 04, 2024

Editas Medicine Reports Q3 2024 Results and Developments - TipRanks

Nov 04, 2024

Nov 04, 2024

Editas: Q3 Earnings Snapshot - The Washington Post

Nov 04, 2024

Nov 04, 2024

Editas Medicine (EDIT) PT Lowered to $5 at RBC Capital - StreetInsider.com

Nov 04, 2024

Nov 04, 2024

Editas downgraded to market perform by Raymond James (NASDAQ:EDIT) - Seeking Alpha

Nov 04, 2024

Nov 04, 2024

Editas Medicine (NASDAQ:EDIT) Downgraded by Raymond James to "Market Perform" - MarketBeat

Nov 04, 2024

Nov 04, 2024

Editas Medicine (EDIT) PT Lowered to $8 at Truist Securities - StreetInsider.com

Nov 04, 2024

Nov 04, 2024

Editas Medicine earnings matched, revenue fell short of estimates By Investing.com - Investing.com Canada

Nov 04, 2024

Nov 04, 2024

Editas Medicine Announces Third Quarter 2024 Results and Business Updates - The Manila Times

Nov 04, 2024

Nov 01, 2024

Editas Medicine stock hits 52-week low at $2.9 amid market challenges - Investing.com Australia

Nov 01, 2024

Oct 31, 2024

Is Editas Medicine, Inc. (EDIT) a Promising Gene Editing Stock? - Insider Monkey

Oct 31, 2024